Related Experiment Video
Updated: Feb 5, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Advances in the Treatment of Metastatic Renal Cell Carcinoma
Paulo Bergerot1, Kathy Burns1, Dhruv Prajapati1
1Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA, 91010, USA.
Abstract:
The treatment landscape for metastatic renal cell carcinoma has constantly been in flux. In 2005, with the advent of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) therapy, the standard of care shifted to agents such as sunitinib and pazopanib. However, more recently there have been datasets, suggesting that next-generation TKIs such as cabozantinib may play an important role in therapy. Furthermore, immunotherapy has had resurgence with the FDA approval of nivolumab with ipilimumab. In the current chapter, we attempt to contextualize available frontline therapies for metastatic renal cell carcinoma with a focus on the CABOSUN and CheckMate 214 clinical trials.
Insights
The treatment for metastatic renal cell carcinoma is evolving. Newer therapies like cabozantinib and immunotherapy combinations (nivolumab with ipilimumab) show promise, shifting the standard of care beyond initial vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs).
Area of Science:
- Oncology
- Medical Research
Background:
- The treatment for metastatic renal cell carcinoma (mRCC) has evolved significantly.
- Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) like sunitinib and pazopanib became standard care after 2005.
- Recent advancements include next-generation TKIs and immunotherapy.
Purpose of the Study:
- To contextualize current frontline therapies for metastatic renal cell carcinoma.
- To analyze the role of emerging treatments in the mRCC landscape.
- To focus on key clinical trials such as CABOSUN and CheckMate 214.
Main Methods:
- Review of clinical trial data and treatment guidelines.
- Comparative analysis of different therapeutic approaches.
- Focus on frontline treatment strategies for mRCC.
Main Results:
- Next-generation TKIs like cabozantinib demonstrate potential efficacy.
- Immunotherapy combinations, such as nivolumab with ipilimumab, have gained FDA approval.
- The CABOSUN and CheckMate 214 trials provide critical data on these newer agents.
Conclusions:
- The frontline treatment of mRCC is dynamic, with new options emerging.
- Cabozantinib and immunotherapy represent significant advancements.
- Understanding these trials is crucial for optimizing mRCC patient care.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
02:22Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
01:20Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
01:23Renal Clearance
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
00:56Extraction: Advanced Methods
01:08Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...